Articles From: Ally Financial Exits TARP with Focus on Future to Alnylam Pharmaceuticals Announces Proposed Public Offering of $450 Million of Common Stock


U.S. Treasury received $2.4 billion in proceeds on investment DETROIT , Dec.
Sign-up for Ally Financial Exits TARP with Focus on Future investment picks
- Net income of $423 million, $0.74 per diluted common share, adjusted EPS of $0.53 - Core pre-tax income of $467 million - Net financing revenue, excluding OID, improved 17 percent year-over-year - Consumer auto originations of $11.8 billion in the quarter - Auto Finance earning assets increased 7 percent, net financing revenue up 6 percent year-over-year - Ally Bank named 'Best Online Bank' for 4th straight year - MONEY® Magazine 2011-2014 - Recognized as 'Best Online Bank' by Kiplinger's Personal Finance NEW YORK , Oct.
Sign-up for Ally Financial Reports Third Quarter 2014 Financial Results investment picks
2015/1/12
WASHINGTON , Jan.
Sign-up for Ally Financial to Make FICO Scores Available to Auto Customers investment picks
2014/11/20
NEW YORK , Nov.
Sign-up for Ally Financial to Present at the Goldman Sachs U.S. Financial Services Conference investment picks
Shares of Ally Financial Inc. (ALLY) rose 3.7% in premarket trade Friday, after the lender announced late Thursday that the Treasury Department launched an offering to sell its remaining shares in Ally.
Sign-up for Ally Financial up in premarket as government exits stake investment picks
2014/12/8
Updated Mobile App and "Click-to-Chat" Added to Improve User Experience DETROIT , Dec.
Sign-up for Ally Launches Enhanced Mobile and Online Tools for Auto Consumers investment picks
2014/11/6
Specialized training designed with a focus on dealership process and opportunities to improve profitability DETROIT , Nov.
Sign-up for Ally Launches New Online Training Courses for RV Dealers investment picks
2015/1/21
"Ally Premier Protection" to Offer Enhanced Benefits for Auto Consumers; Easy-to-Use Technology Platform for Dealers DETROIT , Jan.
Sign-up for Ally Previews New Flagship Vehicle Service Contract and Technology Platform investment picks
2014/12/18
DETROIT , Dec.
Sign-up for Ally Statement on the Launch of U.S. Treasury's Sale of Remaining Common Equity investment picks
Bristol-Myers Squibb Company (NYSE:BMY) today announced late-breaking data from the landmark ALLY Trial investigating a ribavirin-free 12-week regimen of daclatasvir (DCV) in combination with sofosbuvir (SOF) in genotype 3 hepatitis C (HCV) patients, a patient population that has emerged as one of the most difficult to treat.
Sign-up for ALLY Trial Demonstrates High Cure Rates for Investigational Daclatasvir and Sofosbuvir Combination among Genotype 3 Hepatitis C Patients investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=11G028494-001&sourceType=1 http://www.marketwire.com/library/MwGo/2014/12/12/11G028494/Almaden_Minerals_Ltd.-1243461638554.jpg VANCOUVER, BC--(Marketwired - December 15, 2014) - Almaden Minerals Ltd.
Sign-up for Almaden Updates Status of Spin-Out of Mineral Exploration Assets and Royalties investment picks
2014/11/3
AVG Technologies research reveals privacy time bomb as teenagers' lives are diarized online AMSTERDAM and SAN FRANCISCO , Nov.
Sign-up for Almost 1 in 3 Teenagers has Online Regrets by Age 16 investment picks
LOUISVILLE, Ky.
Sign-up for Almost Family Reports Third Quarter 2014 Results investment picks
2014/12/3
A new survey reveals that almost half (48 percent) of Americans are unaware they are required to report their health insurance status on their upcoming 2014 tax returns.
Sign-up for Almost Half of Americans Don’t Realize They Must Report Health Insurance Status on 2014 Tax Returns investment picks
Isis Pharmaceuticals, Inc. (Nasdaq:ISIS) and Alnylam Pharmaceuticals , Inc. (Nasdaq: ALNY), leaders in RNA-targeted therapeutics, announced today they have formed a new agreement, extending their existing strategic partnership – formed originally in 2004 – to lead the development and commercialization of RNA therapeutics.
Sign-up for Alnylam and Isis Form New Agreement, Extending Decade-Long Partnership for Leadership in RNA Therapeutics investment picks
Alnylam Pharmaceuticals , Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, and The Medicines Company (Nasdaq:MDCO), a global biopharmaceutical company focusing on saving lives, alleviating suffering and contributing to the economics of healthcare by focusing on the world’s leading acute/intensive care hospitals, announced today that Alnylam has filed a Clinical Trial Application (CTA) with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 1 clinical trial with ALN-PCSsc, an investigational agent for the treatment of hypercholesterolemia.
Sign-up for Alnylam and The Medicines Company Announce Filing of a Clinical Trial Application to Initiate a Phase 1 Study for ALN-PCSsc, an Investigational, Subcutaneously Administered RNAi Therapeutic Targeting PCSK9 for the Treatment of Hypercholesterolemia investment picks
Alnylam Pharmaceuticals , Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and The Medicines Company (Nasdaq: MDCO), a global biopharmaceutical company focused on hospital care, announced today that Alnylam has initiated a Phase 1 clinical trial with ALN-PCSsc, an investigational agent for the treatment of hypercholesterolemia.
Sign-up for Alnylam and The Medicines Company Announce Initiation of Phase 1 Clinical Trial for ALN-PCSsc, a Subcutaneously Administered Investigational RNAi Therapeutic Targeting PCSK9 for the Treatment of Hypercholesterolemia investment picks
Alnylam Pharmaceuticals , Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that Laurence Reid, Ph.D., the company’s Chief Business Officer, plans to resign from the company, effective December 31, 2014.
Sign-up for Alnylam Announces Planned Departure of Chief Business Officer, Laurence Reid, Ph.D. investment picks
Alnylam Pharmaceuticals , Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today positive initial Phase 2 data with revusiran (ALN-TTRsc), an investigational RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR cardiac amyloidosis.
Sign-up for Alnylam Announces Positive Initial Phase 2 Data with Revusiran (ALN-TTRsc), an Investigational RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR Cardiac Amyloidosis, with up to 98.2% Knockdown of Serum TTR in Patients investment picks
Alnylam Pharmaceuticals , Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today the appointment of Pushkal Garg, M.D., to the position of Senior Vice President, Clinical Development.
Sign-up for Alnylam Appoints Pushkal Garg, M.D., Senior Vice President, Clinical Development investment picks
Alnylam Pharmaceuticals , Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has completed enrollment in its Phase 2 clinical trial with revusiran (re-VOO-si-ran), the recommended International Nonproprietary Name (INN) for ALN-TTRsc.
Sign-up for Alnylam Completes Phase 2 Enrollment and Initiates Open-Label Extension (OLE) Study with Revusiran (ALN-TTRsc), an Investigational RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR Cardiac Amyloidosis investment picks
Alnylam Pharmaceuticals , Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today the election of Michael W.
Sign-up for Alnylam Elects Michael W. Bonney to Its Board of Directors investment picks
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has expanded its hepatic infectious disease pipeline.
Sign-up for Alnylam Expands Hepatic Infectious Disease Pipeline; Adds ALN-HDV for the Treatment of Chronic Hepatitis Delta Virus (HDV) Infection and ALN-PDL for the Treatment of Chronic Liver Infections investment picks
Alnylam Pharmaceuticals , Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that it has filed a Clinical Trial Application (CTA) with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 1/2 clinical trial with ALN-CC5, a subcutaneously administered investigational RNAi therapeutic targeting complement component C5 for the treatment of complement-mediated diseases.
Sign-up for Alnylam Files Clinical Trial Application (CTA) for ALN-CC5, an RNAi Therapeutic Targeting Complement C5 in Development for the Treatment of Complement-Mediated Diseases investment picks
Alnylam Pharmaceuticals , Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that it has filed a Clinical Trial Application (CTA) with the Swedish Medical Products Agency (MPA) to initiate a Phase 1 clinical trial with ALN-AS1, a subcutaneously administered investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS-1) for the treatment of hepatic porphyrias, including acute intermittent porphyria (AIP). Per the filed CTA, the Phase 1 trial of ALN-AS1 will be performed first in AIP patients who are asymptomatic “high excreters” (ASHE) – patients with a mutation in the porphobilinogen deaminase (PBGD) gene and elevated urinary aminolevulinic acid (ALA) and porphobilinogen (PBG) levels, but no recent symptoms of a porphyria attack – and then in AIP patients who experience recurrent porphyria attacks.
Sign-up for Alnylam Files Clinical Trial Application to Initiate a Phase 1 Study for ALN-AS1, a Subcutaneously Administered, Investigational RNAi Therapeutic Targeting Aminolevulinic Acid Synthase-1 (ALAS-1) for the Treatment of Hepatic Porphyrias investment picks
Alnylam Pharmaceuticals , Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today it has initiated the ENDEAVOUR Phase 3 clinical trial of revusiran in transthyretin (TTR)-mediated familial amyloidotic cardiomyopathy (FAC). FAC is one of the predominant clinical manifestations of TTR-mediated amyloidosis (ATTR), and afflicts an estimated 40,000 people worldwide.
Sign-up for Alnylam Initiates ENDEAVOUR Phase 3 Clinical Trial with Revusiran (ALN-TTRsc), an Investigational RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR Cardiac Amyloidosis investment picks
Alnylam Pharmaceuticals , Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today its pipeline growth strategy for development and commercialization of RNAi therapeutics across three Strategic Therapeutic Areas (STArs): Genetic Medicines, Cardio-metabolic Disease, and Hepatic Infectious Disease.
Sign-up for Alnylam Introduces Pipeline Growth Strategy for RNAi Therapeutics in Three Strategic Therapeutic Areas, or “STArs” investment picks
Alnylam Pharmaceuticals , Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today its “Alnylam 2020” guidance for the advancement and commercialization of RNAi therapeutics as a whole new class of innovative medicines.
Sign-up for Alnylam Launches “Alnylam 2020” Guidance for Advancement and Commercialization of RNAi Therapeutics investment picks
Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, today announced that it has commenced an underwritten public offering of shares of its common stock to raise aggregate proceeds of approximately $450 million.
Sign-up for Alnylam Pharmaceuticals Announces Proposed Public Offering of $450 Million of Common Stock investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Ally Financial Exits TARP with Focus on Future to Alnylam Pharmaceuticals Announces Proposed Public Offering of $450 Million of Common Stock
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent